Susceptibility to Ceftriaxone-sulbactam-EDTA in gram negative MDR & non-MDR isolates at tertiary care centre JNMCH Aligarh, Uttar Pradesh

Abstract

Introduction: A rapid increase in multidrug-resistant (MDR) is being reported across India. Ceftriaxone-sulbactam-EDTA (CSE) is a promising therapeutic option available in cases of infections caused by ESBL and MBL producing pathogens proving to be a carbapenem-sparing antibiotic. However, CSE effectiveness needs to be evaluated due to rapidly increasing antimicrobial resistance.

Objectives: Following prospective observational study was directed to generate data on in-vitro susceptibility of MDR and NON-MDR to Ceftriaxone-sulbactam-EDTA (CSE).

Materials and Methods: Gram negative bacterial isolates cultured from various nonrepetitive clinical samples of indoor and outdoor patients of a tertiary care centre of UP for a period of 9 months (1 April 2022 to 31 December 2022) were included in the study. Antimicrobial susceptibility testing to antibiotics was done using Kirby-Bauer disk diffusion and VITEK methods.

Results: During study period, 82.3% (229/278) and 17.6% (49/278) of MDR and Non- MDR gram negative isolates respectively. Among the isolates 51% of MDR and 95% of Non- MDR were found to be susceptible to CSE.

Conclusions: Present study shows that in-vitro susceptibility to CSE varies from 51% to 95% depending on the organism. A trend of increasing resistance in multidrug-resistant (MDR) organisms is being reported across all isolates. Ceftriaxone-sulbactam-EDTA fixed dose combination is a promising therapeutic option in cases of infections caused by MDR (especially ESBL and MBL producing pathogens) acting as carbapenem-sparing antibiotics.

International Journal of Human and Health Sciences Supplementary Issue 02: 2023 Page: S149-S158